Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia

Fabio Giuseppe Liberante, Tara Pouryahya, Mary-Frances McMullin, Shu-Dong Zhang*, Kenneth Ian Mills*

    Research output: Contribution to journalArticle

    2 Downloads (Pure)
    Original languageEnglish
    JournalOncotarget
    Volume7
    Issue number6
    Publication statusPublished - 28 Dec 2015

    Keywords

    • myelodysplastic syndromes (MDS)
    • acute myeloid leukemia (AML)
    • bromocriptine
    • re-purposed
    • therapy

    Cite this